Related Experiment Video
Updated: Mar 23, 2026
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Efficacy of Carperitide in Hemodialysis Patients Undergoing Cardiac Surgery
Akira Sezai1, Shunji Osaka, Hiroko Yaoita
1The Department of Cardiovascular Surgery, Nihon University School of Medicine, Tokyo, Japan.
Insights
Carperitide significantly reduced hospital mortality and improved 2-year survival rates in hemodialysis patients undergoing cardiac surgery. This suggests carperitide offers cardioprotection and may improve renal function in this high-risk group.
Area of Science:
- Cardiology
- Nephrology
- Surgical Outcomes
Background:
- Cardiac surgery in hemodialysis patients has increasing incidence but high mortality.
- Dialysis patients represent a high-risk population for cardiac surgical procedures.
Purpose of the Study:
- To evaluate the impact of carperitide infusion on early and long-term outcomes in dialysis patients undergoing cardiac surgery.
- To compare outcomes between patients receiving carperitide and those who did not.
Main Methods:
- Retrospective analysis of 128 dialysis patients who underwent cardiac surgery.
- Patients were divided into two groups: 63 receiving carperitide infusion and 65 not receiving it.
- Follow-up was conducted for 2 years to assess survival and major adverse cardiovascular and cerebrovascular events (MACCE).
Main Results:
- Hospital mortality was significantly lower in the carperitide group (1.6%) compared to the non-carperitide group (12.3%).
- Two-year actuarial survival rates were higher in the carperitide group (90.5%) versus the non-carperitide group (76.9%).
- The MACCE-free rate at 2 years was also significantly better in the carperitide group (90.5%) compared to the non-carperitide group (67.7%).
Conclusions:
- Carperitide improves early postoperative outcomes in dialysis patients undergoing cardiac surgery.
- Potential mechanisms include early cardioprotection and improved renal function in oliguric patients.
- Further prospective studies are needed to confirm these findings and elucidate the underlying mechanisms.
Purpose:
Recently, performance of cardiac surgery in hemodialysis patients has increased, but the mortality rate is high.
Methods:
We retrospectively examined the early and long-term outcomes in 128 dialysis patients who underwent cardiac surgery with or without carperitide infusion and were followed for 2 years. Sixty-three patients received carperitide infusion during surgery and 65 patients did not.
Results:
The hospital mortality rate was 1.6% in the carperitide group and 12.3% in the non-carperitide group, being significantly lower in the carperitide group. The 2-year actuarial survival rate was 90.5% ± 3.7% in the carperitide group, and 76.9% ± 5.2% in the non-carperitide group, while the major adverse cardiovascular and cerebrovascular events (MACCE)-free rate at 2 years postoperatively was 90.5% ± 3.7% in the carperitide group and 67.7% ± 5.8% in the non-carperitide group.
Conclusions:
These findings suggest that carperitide improves the early postoperative outcome in dialysis patients undergoing cardiac surgery, as has already been demonstrated in non-dialysis patients. An early postoperative cardioprotective effect of carperitide and improvement of renal function in oliguric patients might have contributed to this outcome. However, this was a retrospective study, so a prospective investigation is required to demonstrate the mechanisms involved. In addition, further evaluation of the long-term results would be desirable.
Related Concept Videos
01:30Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
01:25Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
01:26Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
01:25Peritoneal Dialysis III: Nursing Management
01:28Cardiac Catheterization I: Pre-Procedure Overview
01:24Hemodialysis II: Procedure and Complications